Genprex, Inc. (GNPX)

NASDAQ: GNPX · IEX Real-Time Price · USD
2.550
+0.100 (4.08%)
At close: May 17, 2024, 4:00 PM
2.450
-0.100 (-3.92%)
After-hours: May 17, 2024, 7:04 PM EDT
4.08%
Market Cap 5.31M
Revenue (ttm) n/a
Net Income (ttm) -27.63M
Shares Out 2.10M
EPS (ttm) -18.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 21,795
Open 2.485
Previous Close 2.450
Day's Range 2.430 - 2.580
52-Week Range 2.090 - 42.400
Beta -0.54
Analysts Strong Buy
Price Target 10.00 (+292.16%)
Earnings Date May 28, 2024

About GNPX

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase ph... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 29, 2018
Employees 26
Stock Exchange NASDAQ
Ticker Symbol GNPX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for GNPX stock is "Strong Buy" and the 12-month stock price forecast is $10.0.

Price Target
$10.0
(292.16% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024 Acclaim-3 Study Supported by FDA Orphan Drug and Fast Track Designations AUSTIN, Texas , May 14, 2024 /PRNewswire/ -- Genprex...

4 days ago - PRNewsWire

Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors AUSTIN, Texas , May 13, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ...

5 days ago - PRNewsWire

Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner

Ryan Confer Appointed Genprex President and CEO and to its Board of Directors AUSTIN, Texas , May 8, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage g...

9 days ago - PRNewsWire

Genprex to Present and Participate at Upcoming May Investor and Industry Conferences

AUSTIN, Texas , May. 1, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients...

17 days ago - PRNewsWire

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Compelling Data Validates the Potential of Reqorsa® Immunogene Therapy and the Oncoprex® Delivery System as Innovative Cancer Treatments REQORSA Has Anti-Tumor Mechanisms and Ability to Trigger Cancer...

5 weeks ago - PRNewsWire

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Multiple clinical trial sites to be opened under collaboration with large network of community-based oncology practices               Acclaim-3 Study Supported by FDA Orphan Drug and Fast Track Design...

6 weeks ago - PRNewsWire

Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System

NPRL2 Gene Therapy Induces Anti-Tumor Activity in Anti-PD1 Resistant KRAS/STK11 Mutant Non-Small Cell Lung Cancer in a Humanized Mouse Model Provides Additional Preclinical Validation of Oncoprex® Del...

6 weeks ago - PRNewsWire

Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

AUSTIN, Texas , March 22, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patien...

2 months ago - PRNewsWire

Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

AUSTIN, Texas , March 19, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patien...

2 months ago - PRNewsWire

Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

Expands on the previously granted patents covering the use of REQORSA in combination with immune checkpoint inhibitors applicable to Genprex's Acclaim-2 and Acclaim-3 clinical trials AUSTIN, Texas , M...

2 months ago - PRNewsWire

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Reqorsa® Immunogene Therapy May be a Potential Therapy for ALK-Positive Lung Cancer REQORSA has Anti-Tumor Mechanisms that Target and Disrupt the Metabolism of Cancer Cells NPRL2 Gene Therapy Induces ...

2 months ago - PRNewsWire

Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

Reqorsa® Therapy May Be Potential Treatment for ALK-Positive Lung Cancer Three Collaborators Selected to Present Positive Nonclinical Data on Genprex Oncology Program at the 2024 American Association ...

3 months ago - PRNewsWire

Genprex to Present at Upcoming BIO CEO & Investor Conference

Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Feb. 6, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene...

3 months ago - PRNewsWire

Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer

Expects to Complete Enrollment of Phase 2a Expansion Study by the end of 2024 Acclaim-1 Study Has FDA Fast Track Designation AUSTIN, Texas , Feb. 5, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or th...

3 months ago - PRNewsWire

Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024

AUSTIN, Texas , Jan. 31, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patient...

3 months ago - PRNewsWire

Genprex Provides Business Update and Outlook for 2024

Acclaim-1 Phase 2a and Acclaim-3 Phase 1 clinical studies opening for enrollment in January 2024 Poised for FDA guidance regarding diabetes gene therapy program in 2024 AUSTIN, Texas , Jan. 5, 2024 /P...

4 months ago - PRNewsWire

Genprex to Present at BIO-Europe 2023 Conference

Presentation to be held on Tuesday, November 7, 2023 from 4:45 – 5:00 p.m. UTC AUSTIN, Texas , Nov. 1, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage...

7 months ago - PRNewsWire

Genprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers"

Webinar to be held on Friday, October 27, 2023 from 12:30 pm - 1:45 pm Eastern Time AUSTIN, Texas , Oct. 20, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-...

7 months ago - PRNewsWire

Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Acclaim-1 Phase 1 study had no Dose Limiting Toxicity, and results establish Phase 2 Recommended Dose as well as provide data showing efficacy of REQORSA® in combination with Tagrisso® Preclinical res...

8 months ago - PRNewsWire

Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire — Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brand...

8 months ago - GlobeNewsWire

Genprex to Present at Upcoming September Investor Conference

Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Sept. 7, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gen...

9 months ago - PRNewsWire

Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

Strengthens management team with seasoned regulatory expert to support pipeline of gene therapies for the treatment of cancer and diabetes, including two clinical trials in Non-Small Cell Lung Cancer ...

9 months ago - PRNewsWire

Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatment of Small Cell Lung Cancer

ODD is in addition to Three FDA Fast Track Designations Genprex expects to dose the first patient in the­­­­ Acclaim-3 clinical trial in the fourth quarter of 2023  AUSTIN, Texas , Aug. 10, 2023 /PRNe...

10 months ago - PRNewsWire

Genprex Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

AUSTIN, Texas , July 21, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patient...

10 months ago - PRNewsWire

Genprex Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

AUSTIN, Texas , July 19, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patient...

10 months ago - PRNewsWire